MindBio Therapeutics received its initial microdoses of LSD. MindBio announced that its initial delivery of 1,000,000 microdoses of LSD had arrived at its labs, following a secure chain of custody, for process in preparation for two separate Phase 2 take home LSD-Microdosing Clinical Trials, which are both fully funded. This LSD will be used to create a novel sublingual formulation for LSD microdosing.

All pharmaceutical medicines need to be made to the standard of Good Manufacturing Practices (GMP) which require manufacturers to ensure that their products are traceable, safe, pure and effective for human consumption. MindBio's CEO Justin Hanka recently visited the company's Canadian manufacturer, which is fully licensed by the Canadian Government to manufacture GMP grade LSD for the pharmaceutical industry. The company recently announced that ethics approval has been received for a world's first Phase 2a take home LSD-Microdosed clinical trial in patients with Major Depressive Disorder, along with approval by the Clinical Trials Ministry.

In this open-label trial in 20 patients with major depressive disorder, the tolerability and feasibility of an 8 week regimen of LSD-Microdosing will be tested. The results will inform a continuation trial, a much larger Phase 2b randomized triple-dummy active placebo controlled trial. In 2022, MindBio's Phase 1 take-home LSD-Microdosing clinical trial, 80 healthy male volunteers were randomised into an LSD group and a Placebo group, receiving 14 doses every 3 days for 6 weeks, with the first doses given in a supervised laboratory setting, and the other doses self-administered at home.

The advantage of microdosing LSD as opposed to macrodosing is that patients can take the drug and then get on with their day in much the same way they would when taking anti-depressant medication.